Affinage

CERS6

Ceramide synthase 6 · UniProt Q6ZMG9

Length
384 aa
Mass
44.9 kDa
Annotated
2026-06-09
45 papers in source corpus 22 papers cited in narrative 22 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CERS6 (LASS6) encodes an endoplasmic reticulum-resident ceramide synthase that preferentially generates short-chain C14:0 and C16:0 ceramides from sphingoid bases and acyl-CoA, with its conserved Lag1/homeodomain catalytic motif oriented so the N-terminus faces the ER lumen and the C-terminus faces the cytosol (PMID:15823095, PMID:16211262). CerS6-derived C16:0 ceramide is a central mediator of metabolic dysfunction: tissue-specific knockout in adipose and liver reduces C16:0 ceramide, increases energy expenditure, and protects against diet-induced obesity and glucose intolerance (PMID:25295788), an effect reproduced by hepatic antisense knockdown that improves insulin sensitivity in obese models (PMID:30655217), and extended to hypothalamic POMC and SF-1 neurons where CerS6 deletion preserves mitochondrial morphology and leptin sensitivity during lipotoxicity (PMID:38016943). Mechanistically, CerS6 ceramide drives mitochondrial and ER stress to engage innate immunity and cell-death pathways: it binds VDAC1 at Glu59 to trigger mtDNA leakage and cGAS-STING activation in podocytes (PMID:39934147), binds the mitophagy receptor BNIP3 to block its LC3 interaction and provoke STING/NLRP3 signaling in alveolar epithelium (PMID:42159698), and inhibits PINK1/Parkin mitophagy to promote renal fibrosis (PMID:37458434). In cancer, CerS6 forms a direct complex with LASP1 and actin at lamellipodia to drive RAC1-dependent migration and metastasis (PMID:32902157, PMID:37345118), and can also act ceramide-independently by stabilizing RPN1 to activate IRE1-XBP1 signaling (PMID:41203639). CERS6 expression is controlled at multiple levels — direct p53 promoter binding (PMID:27302066), AKT1/FOXP3 (PMID:34343636), CEBPγ (PMID:33934437), and CBX4-HDAC5 (PMID:41395279) transcriptional inputs, FTO-dependent m6A mRNA stability (PMID:37734910) — and post-translationally through CK2α-mediated C-terminal phosphorylation and CD36-dependent protein stabilization (PMID:39461238, PMID:35654350).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 2005 High

    Established that CERS6 is a bona fide ceramide synthase with defined substrate preference and membrane topology, distinguishing it from other CerS family members.

    Evidence Overexpression with ceramide species profiling, N-glycosylation analysis, and proteinase K protection in cultured cells

    PMID:15823095

    Open questions at the time
    • Substrate preference shown by overexpression, not reconstituted enzymology
    • Physiological tissue contexts of C14/C16 output not defined
  2. 2005 Low

    Defined the gene's domain architecture, chromosomal location, and conservation, providing the molecular framework but no functional test.

    Evidence Bioinformatic genomic and phylogenetic analysis

    PMID:16211262

    Open questions at the time
    • Purely computational with no functional experiment
    • Tissue expression inferred in silico
  3. 2014 High

    Resolved which ceramide synthase drives obesity-associated C16:0 ceramide accumulation, placing CerS6 causally upstream of metabolic dysfunction.

    Evidence Whole-body, BAT- and liver-specific knockout mice with MS ceramide profiling and metabolic phenotyping

    PMID:25295788

    Open questions at the time
    • Downstream molecular effectors of C16:0 ceramide not yet identified
    • Did not address neuronal or immune contributions
  4. 2016 High

    Identified CERS6 as a direct p53 transcriptional target, linking ceramide synthesis to a tumor-suppressor stress program.

    Evidence Luciferase reporters with WT vs R175H p53, in vitro IP, EMSA, and pharmacological p53 activation

    PMID:27302066

    Open questions at the time
    • Cellular consequence of p53-driven CerS6 induction not fully resolved
    • Non-canonical response element function not validated by ChIP in vivo
  5. 2016 Medium

    Connected CerS6 levels to a GLUT1/WNT5A axis controlling melanoma invasion and glycolysis, indicating context-dependent tumor-suppressive behavior.

    Evidence siRNA knockdown, microarray, and GLUT1-silencing rescue in melanoma cell lines

    PMID:26934938

    Open questions at the time
    • Single lab, cell-line only
    • Direct ceramide link to GLUT1 regulation not established
  6. 2018 Medium

    Showed CerS6 can restore chemosensitivity by promoting mitochondrial fission and apoptosis, framing it as pro-death in some cancer settings.

    Evidence Lentiviral overexpression/knockdown in cisplatin-resistant OSCC cells plus xenografts

    PMID:30054909

    Open questions at the time
    • Mechanism linking ceramide to calpain/mitochondrial fission not defined
    • Single lab
  7. 2019 High

    Demonstrated CerS6 is pharmacologically actionable for metabolic disease via hepatic knockdown, corroborating genetic KO data.

    Evidence ASO knockdown in ob/ob and HFD mice with ceramide profiling and metabolic tests

    PMID:30655217

    Open questions at the time
    • Tissue selectivity of ASO incomplete
    • Molecular mechanism of metabolic improvement not addressed here
  8. 2020 High

    Revealed a migration/metastasis function via RAC1-dependent lamellipodia, establishing a pro-tumorigenic role distinct from the metabolic axis.

    Evidence Reciprocal knockdown/overexpression in NSCLC with lung metastasis model and miR-101 luciferase analysis

    PMID:32902157

    Open questions at the time
    • How ceramide alters RAC1 localization mechanistically unclear
    • miR-101 regulation correlative
  9. 2021 Medium

    Identified transcriptional inputs (CEBPγ Y-box binding) and a signaling axis (AKT1-FOXP3) that induce CERS6 in cancer.

    Evidence Promoter luciferase, ChIP, Co-IP, phosphorylation assays, and knockdowns in NSCLC and pancreatic models

    PMID:33934437 PMID:34343636

    Open questions at the time
    • CEBPγ binding lacks ChIP confirmation
    • Single-lab regulatory axes not cross-validated
  10. 2022 Medium

    Established post-translational control of CerS6 activity and stability through CK2α phosphorylation of its cytosolic C-terminus.

    Evidence Cycloheximide chase, CK2α/CerS6 western blots, and ceramide profiling in NASH rat model

    PMID:35654350

    Open questions at the time
    • Direct CK2α phosphorylation assay not described
    • Degradation machinery not identified
  11. 2023 High

    Defined CerS6 as a driver of mitochondrial/ER stress across tissues, acting through direct interaction with VDAC1, BNIP3, and PINK1 to control mtDNA leakage and mitophagy.

    Evidence Cell-type-specific KO/overexpression in podocytes and hypothalamic neurons, Co-IP, docking, and pathway readouts

    PMID:37230220 PMID:37458434 PMID:38016943 PMID:39934147 PMID:42159698

    Open questions at the time
    • Ceramide-PINK1 binding supported only by docking
    • Whether ceramide acts directly or via membrane perturbation on each target unresolved
  12. 2023 Medium

    Showed CerS6 forms a direct LASP1-actin complex at lamellipodia, providing a physical mechanism for its migration function.

    Evidence Co-IP with LC-MS/MS partner identification, co-localization, reciprocal knockdowns, and C16 ceramide rescue in lung cancer cells

    PMID:37345118

    Open questions at the time
    • LIM-domain requirement inferred not mapped
    • Single lab, partial ceramide rescue
  13. 2024 High

    Identified m6A (FTO) control of CerS6 mRNA stability and CD36-dependent protein stabilization, linking CerS6 to mucosal immunity and sepsis inflammation.

    Evidence FTO and CD36 conditional KO mice with MeRIP-seq, sphingolipid profiling, and inflammatory readouts

    PMID:37734910 PMID:39461238

    Open questions at the time
    • Molecular mechanism of CD36-mediated stabilization not characterized
    • Whether S1P accumulation reflects a general CerS6-loss consequence unclear
  14. 2025 Medium

    Uncovered a ceramide-independent function in which CerS6 stabilizes RPN1 to activate IRE1-XBP1 signaling, plus additional transcriptional regulators (CBX4-HDAC5, E4BP4-PRDM16).

    Evidence Ubiquitination and IRE1-XBP1 assays in ESCC; luciferase/ChIP and Co-IP in AML and brown adipose models (one preprint)

    PMID:41203639 PMID:41395279 PMID:bio_10.1101_2025.05.19.652826

    Open questions at the time
    • Non-catalytic RPN1-stabilizing mechanism single-lab
    • E4BP4 enhancer mechanism from preprint not peer-reviewed

Open questions

Synthesis pass · forward-looking unresolved questions
  • How CerS6 ceramide products are physically delivered to and recognized by distinct effector proteins (VDAC1, BNIP3, PINK1) versus acting through bulk membrane biophysics remains unresolved.
  • No structural model of CerS6 catalytic or interaction interfaces
  • Direct biochemical validation of ceramide-protein binding lacking for most effectors

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 2 GO:0016787 hydrolase activity 1
Localization
GO:0005783 endoplasmic reticulum 1 GO:0005856 cytoskeleton 1
Pathway
R-HSA-168256 Immune System 3 R-HSA-1430728 Metabolism 2 R-HSA-9612973 Autophagy 2
Partners
BNIP3CD36LASP1PINK1RPN1VDAC1

Evidence

Reading pass · 22 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2005 CERS6 (Lass6) encodes a ceramide synthase that preferentially produces short-chain ceramides (C14:0 and C16:0) when overexpressed in cultured cells, with a distinct substrate preference for saturated/unsaturated fatty acyl-CoA compared to Lass5. The N-terminus of CERS6 faces the luminal side of the ER membrane (demonstrated by N-glycosylation of the N-terminal Asn residue), while the C-terminus faces the cytosolic side (demonstrated by proteinase K digestion assay), establishing the topology of the conserved Lag1 motif. Overexpression in cultured cells with ceramide species profiling; N-glycosylation analysis; proteinase K digestion assay; Northern blotting for tissue expression The Biochemical journal High 15823095
2005 LASS6 (CERS6) protein contains a homeodomain and LAG1 domain, maps to human chromosome 2q24.3, and is conserved in vertebrates (mouse and zebrafish orthologs identified). The gene spans ~318 kb and is broadly expressed across tissues. Bioinformatic/genomic database screening and phylogenetic analysis; in silico expression analysis International journal of molecular medicine Low 16211262
2014 CerS6 is the ceramide synthase responsible for C16:0 ceramide production in adipose tissue and liver; whole-body and tissue-specific (BAT- and liver-specific) CerS6 knockout mice show reduced C16:0 ceramides, increased energy expenditure, and protection from high-fat-diet-induced obesity and glucose intolerance, placing CerS6-derived C16:0 ceramide as a mediator of metabolic dysfunction in obesity. Conditional knockout mouse models (whole-body, BAT-specific, liver-specific CerS6 deletion); ceramide profiling by mass spectrometry; metabolic phenotyping (glucose tolerance tests, energy expenditure measurements) Cell metabolism High 25295788
2016 CerS6 is a direct transcriptional target of p53: the CerS6 promoter is activated by p53 in luciferase assays (transcriptionally inactive R175H mutant fails to activate), purified p53 binds within the CerS6 promoter (91 bp upstream to 60 bp downstream of TSS) as shown by in vitro immunoprecipitation and gel shift assays, with a single non-canonical p53 response element upstream of the TSS identified as the key binding motif. Treatment with Nutlin-3 or low-dose actinomycin D (non-genotoxic p53 activators) elevates CerS6 mRNA and protein. Luciferase reporter assays with wild-type vs. R175H p53 mutant; in vitro immunoprecipitation; electrophoretic mobility shift assay (EMSA/gel shift); pharmacological p53 activation (Nutlin-3, actinomycin D) The Journal of biological chemistry High 27302066
2016 Silencing of CerS6 in melanoma cell lines increases invasion and glycolysis by upregulating GLUT1 expression, which in turn downregulates WNT5A. Silencing GLUT1 in CerS6-silenced cells restores WNT5A expression and reduces invasion/proliferation, placing CerS6 upstream of a GLUT1/WNT5A axis regulating melanoma malignancy. siRNA-mediated CerS6 knockdown; gene microarray; qPCR and western blot validation; invasion and proliferation assays; GLUT1 silencing rescue experiment Oncology reports Medium 26934938
2018 CerS6 overexpression in cisplatin-resistant oral squamous cell carcinoma (OSCC) cells restores cisplatin sensitivity by enhancing mitochondrial fission, promoting apoptosis, and attenuating cisplatin-induced autophagy; this is associated with altered calpain expression. CerS6 knockdown has the opposite effect. Lentiviral CerS6 overexpression in resistant cells; mitochondrial morphology assessment; apoptosis assays; autophagy marker analysis; xenograft tumor model Journal of cellular physiology Medium 30054909
2019 Antisense oligonucleotide (ASO)-mediated knockdown of CerS6 predominantly in the liver (~90% reduction in CerS6 mRNA) reduces C16:0 ceramide levels by ~50% in liver and plasma, decreases body weight gain, reduces fat mass, lowers blood glucose (HbA1c), and improves oral glucose tolerance and insulin sensitivity in ob/ob and HFD-induced obese mouse models, confirming CerS6 as a therapeutically actionable target for hepatic C16:0 ceramide production. Antisense oligonucleotide (ASO) pharmacological knockdown in vivo; ceramide profiling; glucose and insulin tolerance tests; body composition analysis in two obese mouse models Molecular metabolism High 30655217
2020 CERS6 is required for cell migration and invasion in non-small cell lung cancer (NSCLC): CERS6 knockdown alters the ceramide profile, suppresses RAC1-positive lamellipodia/ruffling formation, reduces cell migration in vitro, and attenuates lung metastasis in mice; forced CERS6 expression produces the opposite phenotype. CERS6 overexpression in NSCLC is driven at least in part by reduced miR-101 expression. CERS6 knockdown and overexpression in NSCLC cell lines; ceramide profiling; RAC1 localization/lamellipodia assays; in vivo lung metastasis mouse model; luciferase analysis for miR-101 regulation Journal of cellular and molecular medicine High 32902157
2021 CEBPγ transcription factor directly binds the Y-box cis-acting element in the CERS6 promoter to induce CERS6 expression, promoting ceramide-dependent lamellipodia formation and cell migration in NSCLC. YBX1 independently regulates lamellipodia and migration but without specific binding to the Y-box for CERS6 induction. Luciferase analysis of CERS6 promoter; siRNA knockdown of CEBPγ and YBX1; correlation analysis in 149 NSCLC patient database records; lamellipodia and migration assays Cancer science Medium 33934437
2021 AKT1 phosphorylates FOXP3 at S418, which decreases FOXP3 binding to the CERS6 promoter and thereby induces CerS6 expression. CerS6-derived C16-ceramide produced downstream promotes accumulation of mutant p53 in pancreatic ductal adenocarcinoma. This AKT1/FOXP3 axis drives CERS6 transcription and pancreatic tumorigenesis. Co-immunoprecipitation (AKT1-FOXP3 interaction); phosphorylation assays (S418 site); chromatin immunoprecipitation (FOXP3 binding to CERS6 promoter); CerS6 overexpression/knockdown; ceramide profiling; colony formation, invasion, and tumor formation assays Cancer letters Medium 34343636
2023 CERS6 and LASP1 form a direct protein complex (with the LASP1 LIM domain likely required for interaction) that co-localizes on lamellipodia in lung cancer cell lines. Both CERS6 and LASP1 independently co-immunoprecipitate with actin, but these interactions are markedly reduced when the LASP1-CERS6 complex is abolished. Silencing either CERS6 or LASP1 suppresses cell migration and lamellipodia formation; ectopic addition of C16 ceramide partially rescues these phenotypes. Co-immunoprecipitation; liquid chromatography-tandem mass spectrometry (LC-MS/MS) for binding partner identification; co-localization microscopy; siRNA knockdown of CERS6 and/or LASP1; cell migration and lamellipodia formation assays; C16 ceramide rescue experiment Cancers Medium 37345118
2023 CerS6 deficiency in hypothalamic neurons (conditional KO) attenuates HFD-induced weight gain and improves glucose metabolism. Neuron-specific CerS6 deletion in POMC-expressing cells prevents diet-induced mitochondrial morphology alterations and improves cellular leptin sensitivity, while CerS6 deletion in SF-1-expressing neurons alters feeding behavior and alleviates adverse metabolic effects. CerS6-derived ceramides promote ER/mitochondrial stress in hypothalamic lipotoxicity. Conditional neuronal CerS6 knockout mice (POMC-Cre and SF-1-Cre drivers); mitochondrial morphology analysis; leptin sensitivity assays; metabolic phenotyping (glucose tolerance, insulin sensitivity, body weight, food intake); palmitate treatment of cultured hypothalamic neurons in vitro Nature communications High 38016943
2023 CERS6-derived C16:0 ceramide (and C14:0 ceramide) inhibit PINK1-mediated mitophagy in renal tubular epithelial cells, likely by binding directly to the PINK1 protein (supported by automated docking analysis). CerS6 deficiency in db/db diabetic mice restores PINK1/Parkin-mediated mitophagy, reduces damaged mitochondria, and attenuates interstitial fibrosis. Inhibiting PINK1 in CERS6-knockdown HK-2 cells abolishes the protective effect. CerS6 knockout in db/db mice; ceramide profiling (LC-MS/MS); mitophagy assays (PINK1/Parkin pathway markers); CERS6 knockdown in HK-2 cells with PINK1 inhibition rescue; automated molecular docking of ceramides to PINK1 American journal of physiology. Cell physiology Medium 37458434
2023 High glucose promotes CerS6 synthesis through the TLR4/IKKβ signaling pathway in human liver (LO2) cells. CerS6-derived ceramide promotes mitochondrial oxidative stress (mtROS), and CerS6 knockout attenuates mitochondrial oxidative stress, inhibits ferroptosis, and ameliorates markers of liver injury and fibrosis under high-glucose conditions. Pharmacological TLR4/IKKβ pathway manipulation; CerS6 knockdown and overexpression in LO2 cells; mitochondrial ROS measurement; ferroptosis marker analysis; Mito-TEMPO antioxidant intervention Molecular and cellular endocrinology Medium 37230220
2024 FTO (m6A demethylase) deficiency increases m6A modification on CerS6 mRNA, decreasing its stability and reducing CerS6 expression in intestinal epithelial cells. Reduced CerS6 leads to S1P accumulation, which triggers proinflammatory macrophage activation (secreting SAA1/3) and ultimately induces Th17 cell differentiation, aggravating ulcerative colitis. Conditional FTO knockout mice (Villin-Cre); RNA and methylated RNA immunoprecipitation sequencing (MeRIP-seq); ceramide/S1P profiling by LC-MS; macrophage conditioned medium treatment; real-time PCR and 16S rRNA sequencing Gut High 37734910
2024 CerS6-derived ceramide (d18:1/16:0) binds to the mitochondrial channel protein VDAC1 at Glu59, initiating mitochondrial DNA (mtDNA) leakage, activating the cGAS-STING signaling pathway, and promoting inflammatory responses in kidney podocytes in diabetic kidney disease. Podocyte-specific CerS6 knockout ameliorates glomerular injury and inflammation, while podocyte-specific CerS6 overexpression induces proteinuria. Podocyte-specific CerS6 knockout and overexpression in diabetic mice; ceramide-VDAC1 binding analysis (including identification of Glu59 residue); mtDNA leakage assays; cGAS-STING pathway activation measurement; histology and proteinuria assessment Nature communications High 39934147
2024 CD36 regulates CerS6 protein stability: CD36 deficiency reduces CerS6 protein expression and reduces LPS-induced inflammatory responses. CerS6-derived C16-ceramide augments LPS-induced inflammation via endoplasmic reticulum stress, activating MAPK, NF-κB, and inflammasome signaling. CerS6 protein expression and LPS-induced lethality were reduced in CD36 knockout mice. CD36 knockout mice (in vivo LPS sepsis model); CerS6 protein stability assays; ER stress markers; MAPK and NF-κB pathway analyses; inflammasome complex formation and cytokine measurement International immunopharmacology Medium 39461238
2022 CerS6 protein stability is regulated by casein kinase 2α (CK2α), which phosphorylates the C-terminal region of CerS6 to increase its enzymatic activity. The herbal compound DHG promotes CerS6 protein degradation (shown by cycloheximide assay) and attenuates CK2α expression, reducing CerS6 protein levels and decreasing C16:0 ceramide in NASH rats. Cycloheximide (CHX) chase assay for CerS6 protein degradation; western blot for CK2α and CerS6 protein; RT-qPCR for mRNA; ceramide profiling by HPLC-QQQ-MS/MS in MCD diet rat model Journal of ethnopharmacology Medium 35654350
2025 CERS6 promotes esophageal squamous cell carcinoma (ESCC) proliferation through a non-ceramide mechanism: CERS6 sustains the stability of RPN1 (ribophorin 1) by inhibiting its ubiquitination, and downstream activation of the RPN1-IRE1-XBP1 signaling pathway reduces ER stress and ROS. ASO-mediated CERS6 targeting inhibits ESCC growth through this same pathway. CERS6 overexpression/knockdown in ESCC cells; ubiquitination assays for RPN1; IRE1-XBP1 pathway activation analysis; ROS measurement; xenograft tumor model; ASO treatment Cell death discovery Medium 41203639
2024 CerS6 interacts directly with the mitophagy receptor BNIP3, disrupting BNIP3's binding to LC3 and thereby inhibiting mitophagy. Impaired mitochondrial clearance promotes cytoplasmic release of mtDNA and activates STING/NLRP3 signaling in AT2 cells during acute lung injury. AT2-cell-specific CerS6 knockout attenuates apoptosis, inflammation, oxidative stress, and barrier disruption in ALI mouse models. AT2-cell-specific CerS6 knockout mice (LPS and CLP models); co-immunoprecipitation of CerS6 with BNIP3; LC3-BNIP3 interaction assay; mtDNA leakage measurement; STING/NLRP3 pathway analysis; RNA-Seq Cellular and molecular life sciences : CMLS Medium 42159698
2025 E4BP4 acts as a transcriptional repressor of Cers6 by interacting with PRDM16 and binding to a 65 kb upstream enhancer region of the Cers6 gene in brown adipose tissue, reducing CerS6 expression and C16:0 ceramide levels. E4BP4 gain-of-function prevents obesity-induced mitochondrial fragmentation and oxidative dysfunction in BAT and improves systemic glucose homeostasis independent of weight loss. E4BP4 gain-of-function in BAT; Cers6 mRNA and C16:0 ceramide measurement; PRDM16 co-immunoprecipitation with E4BP4; enhancer region binding analysis; mitochondrial morphology and function assays; metabolic phenotyping bioRxivpreprint Medium bio_10.1101_2025.05.19.652826
2025 The CBX4-HDAC5-CERS6 axis regulates sphingolipid metabolism in acute myeloid leukemia: CBX4 knockdown significantly downregulates CERS6 mRNA and protein expression. CBX4 indirectly regulates CERS6 transcription by suppressing HDAC5, and dual-luciferase reporter assays confirmed that HDAC5 directly targets the CERS6 promoter region. siRNA-mediated CBX4 knockdown; dual-luciferase reporter assay (HDAC5 targeting CERS6 promoter); chromatin immunoprecipitation; ceramide measurement; RNA sequencing and proteomics in THP-1 and KG-1 cell lines American journal of cancer research Medium 41395279

Source papers

Stage 0 corpus · 45 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2014 Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell metabolism 594 25295788
2005 Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. The Biochemical journal 336 15823095
2019 The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach. Molecular metabolism 162 30655217
2019 Long noncoding RNA CERS6-AS1 functions as a malignancy promoter in breast cancer by binding to IGF2BP3 to enhance the stability of CERS6 mRNA. Cancer medicine 59 31701672
2024 Disruption of CerS6-mediated sphingolipid metabolism by FTO deficiency aggravates ulcerative colitis. Gut 48 37734910
2016 CerS6 Is a Novel Transcriptional Target of p53 Protein Activated by Non-genotoxic Stress. The Journal of biological chemistry 45 27302066
2018 CerS6 regulates cisplatin resistance in oral squamous cell carcinoma by altering mitochondrial fission and autophagy. Journal of cellular physiology 42 30054909
2023 CerS6-dependent ceramide synthesis in hypothalamic neurons promotes ER/mitochondrial stress and impairs glucose homeostasis in obese mice. Nature communications 39 38016943
2021 LncRNA CERS6-AS1 promotes proliferation and metastasis through the upregulation of YWHAG and activation of ERK signaling in pancreatic cancer. Cell death & disease 38 34168120
2023 CERS6-derived ceramides aggravate kidney fibrosis by inhibiting PINK1-mediated mitophagy in diabetic kidney disease. American journal of physiology. Cell physiology 33 37458434
2021 AKT1/FOXP3 axis-mediated expression of CerS6 promotes p53 mutant pancreatic tumorigenesis. Cancer letters 27 34343636
2025 CerS6 links ceramide metabolism to innate immune responses in diabetic kidney disease. Nature communications 26 39934147
2020 lncRNA CERS6-AS1 as ceRNA promote cell proliferation of breast cancer by sponging miR-125a-5p to upregulate BAP1 expression. Molecular carcinogenesis 26 32808708
2016 Silencing of CerS6 increases the invasion and glycolysis of melanoma WM35, WM451 and SK28 cell lines via increased GLUT1-induced downregulation of WNT5A. Oncology reports 22 26934938
2020 CERS6 required for cell migration and metastasis in lung cancer. Journal of cellular and molecular medicine 21 32902157
2023 IGF2BP3 Worsens Lung Cancer through Modifying Long Non-coding RNA CERS6-AS1/microRNA-1202 Axis. Current medicinal chemistry 17 35702784
2021 Long non-coding RNA CERS6-AS1 facilitates the oncogenicity of pancreatic ductal adenocarcinoma by regulating the microRNA-15a-5p/FGFR1 axis. Aging 17 33581689
2021 Long Noncoding RNA CERS6-AS1 Accelerates the Proliferation and Migration of Pancreatic Cancer Cells by Sequestering MicroRNA-15a-5p and MicroRNA-6838-5p and Modulating HMGA1. Pancreas 17 33939677
2005 LASS6, an additional member of the longevity assurance gene family. International journal of molecular medicine 17 16211262
2022 CERS6-AS1 contributes to the malignant phenotypes of colorectal cancer cells by interacting with miR-15b-5p to regulate SPTBN2. The Kaohsiung journal of medical sciences 15 35146902
2021 CEBPγ facilitates lamellipodia formation and cancer cell migration through CERS6 upregulation. Cancer science 15 33934437
2022 CERS6-AS1 Facilitates Oncogenesis and Restrains Ferroptosis in Papillary Thyroid Carcinoma by Serving as a ceRNA through miR-497-5p/LASP1 Axis. Annals of clinical and laboratory science 14 35777805
2023 lncRNA CERS6-AS1 upregulates the expression of ANLN by sponging miR-424-5p to promote the progression and drug resistance of lung adenocarcinoma. Non-coding RNA research 12 38094657
2022 CERS6-AS1 promotes cell proliferation and represses cell apoptosis in pancreatic cancer via miR-195-5p/WIPI2 axis. The Kaohsiung journal of medical sciences 12 35199935
2022 Danhe granule ameliorates nonalcoholic steatohepatitis and fibrosis in rats by inhibiting ceramide de novo synthesis related to CerS6 and CerK. Journal of ethnopharmacology 12 35654350
2023 CerS6 triggered by high glucose activating the TLR4/IKKβ pathway regulates ferroptosis of LO2 cells through mitochondrial oxidative stress. Molecular and cellular endocrinology 11 37230220
2022 Long noncoding RNA CERS6-AS1 modulates glucose metabolism and tumor progression in hepatocellular carcinoma by promoting the MDM2/p53 signaling pathway. Cell death discovery 11 35927226
2023 Ceramide synthase 6 (CerS6) is upregulated in alcohol-associated liver disease and exhibits sex-based differences in the regulation of energy homeostasis and lipid droplet accumulation. Molecular metabolism 9 37714377
2024 Machine learning model identifies genetic predictors of cisplatin-induced ototoxicity in CERS6 and TLR4. Computers in biology and medicine 7 39488053
2023 LASP1, CERS6, and Actin Form a Ternary Complex That Promotes Cancer Cell Migration. Cancers 6 37345118
2022 The role of lncRNA CERS6-AS1 in cancer and its molecular mechanisms: A systematic review and meta-analysis. Pathology, research and practice 6 36580796
2022 MYC-activated CERS6-AS1 sponges miR-6838-5p and regulates the expression of RUBCNL in colorectal cancer. Cellular and molecular biology (Noisy-le-Grand, France) 5 37130182
2024 The effects of restraint stress on ceramide metabolism disorders in the rat liver: the role of CerS6 in hepatocyte injury. Lipids in health and disease 4 38431645
2024 CD36 deficiency protects lipopolysaccharide-induced sepsis via inhibiting CerS6-mediated endoplasmic reticulum stress. International immunopharmacology 4 39461238
2023 CERS6 antisense RNA 1 promotes colon cancer via upregulating mitochondrial calcium uniporter. European journal of clinical investigation 4 36628448
2023 LncRNA CERS6-AS1 Is a Tumor Promoter in Cervical Cancer by Sponging miR-195-5p. Annals of clinical and laboratory science 4 36889776
2022 Effect and Mechanism of lncRNA CERS6-AS1 on the Biological Behavior of Prostate Cancer Cell. Applied bionics and biomechanics 4 35706508
2024 Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma. Leukemia 2 39003397
2022 LncRNA CERS6-AS1, sponging miR-6838-5p, promotes proliferation and invasion in cervical carcinoma cells by upregulating FOXP2. Histology and histopathology 2 36444938
2025 CERS6 promotes esophageal squamous cell carcinoma proliferation by increasing the stability of RPN1. Cell death discovery 1 41203639
2026 CerS6 orchestrates mitochondrial-immune crosstalk via BNIP3-dependent mitophagy suppression and mtDNA-STING/NLRP3 activation in acute lung injury. Cellular and molecular life sciences : CMLS 0 42159698
2025 LncRNA CERS6 - AS1 mediates the IGF2BP1/LIN28B axis to promote proliferation, migration and invasion in ovarian cancer. Biochimica et biophysica acta. Proteins and proteomics 0 41290121
2025 Exploring the hub gene CERS6 as a therapeutic target in type 1 diabetes through a bioinformatics and network analyst approach. Scientific reports 0 41326554
2025 Role and mechanism of the CBX4-HDAC5-CERS6 axis in disrupting sphingomyelin metabolism in acute myeloid leukemia. American journal of cancer research 0 41395279
2023 Retracted: Effect and Mechanism of lncRNA CERS6-AS1 on the Biological Behavior of Prostate Cancer Cell. Applied bionics and biomechanics 0 37829519

Missed literature

Know a paper Affinage missed for CERS6? Flag it for the maintainers and the community.

No submissions yet.